Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges
CNBC Stocks· Aug 4, 2026 · 10:34 AM
Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.
This is a summary. Read the complete story at CNBC Stocks below.
Read full article at CNBC StocksRelated Stories
stocksabout 7 hours ago
Exclusive-Anthropic considers releasing new AI model ahead of IPO, sources say
Investing.com
stocksabout 7 hours ago
Morgan Stanley private credit fund redemption requests remain elevated in third quarter
Investing.com
stocksabout 7 hours ago
Gemini hacked three companies in first known breakout by Google’s AI
Investing.com